317 related articles for article (PubMed ID: 32139141)
1. Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Surgery; 2020 Dec; 168(6):994-1002. PubMed ID: 32139141
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
3. Significance of aggressive surgery for an invasive carcinoma derived from an intraductal papillary mucinous neoplasm diagnosed preoperatively as borderline resectable.
Aimoto T; Mizutani S; Kawano Y; Suzuki H; Uchida E
J Nippon Med Sch; 2013; 80(5):371-7. PubMed ID: 24189355
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study.
Lucocq J; Hawkyard J; Haugk B; Mownah O; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari B; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; Van Laarhoven S; Robertson F; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Rajesh S; Jeffery F; Connor S; Cameron A; Jamieson N; Sheen A; Mittal A; Samra J; Gill A; Roberts K; Søreide K; Pandanaboyana S
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38659247
[TBL] [Abstract][Full Text] [Related]
5. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
6. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathological features and long term outcome related to histopathological group.
De Moor V; Arvanitakis M; Nagy N; Coppens E; Delhaye M; Closset J
Hepatogastroenterology; 2012; 59(114):565-9. PubMed ID: 22353525
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated With Invasive Intraductal Papillary Mucinous Carcinoma of the Pancreas.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
JAMA Surg; 2017 Mar; 152(3):e165054. PubMed ID: 28122068
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
10. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.
Turrini O; Waters JA; Schnelldorfer T; Lillemoe KD; Yiannoutsos CT; Farnell MB; Sarr MG; Schmidt CM
HPB (Oxford); 2010 Sep; 12(7):447-55. PubMed ID: 20815853
[TBL] [Abstract][Full Text] [Related]
11. Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N
Ann Surg Oncol; 2007 Nov; 14(11):3174-80. PubMed ID: 17694416
[TBL] [Abstract][Full Text] [Related]
12. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
[TBL] [Abstract][Full Text] [Related]
13. Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio.
Partelli S; Fernandez-Del Castillo C; Bassi C; Mantovani W; Thayer SP; Crippa S; Ferrone CR; Falconi M; Pederzoli P; Warshaw AL; Salvia R
Ann Surg; 2010 Mar; 251(3):477-82. PubMed ID: 20142730
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
Swartz MJ; Hsu CC; Pawlik TM; Winter J; Hruban RH; Guler M; Schulick RD; Cameron JL; Laheru DA; Wolfgang CL; Herman JM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):839-44. PubMed ID: 19647950
[TBL] [Abstract][Full Text] [Related]
15. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas.
Hirono S; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
Surgery; 2016 Aug; 160(2):306-17. PubMed ID: 27236360
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies.
Yogi T; Hijioka S; Imaoka H; Mizuno N; Hara K; Tajika M; Tanaka T; Ishihara M; Shimizu Y; Hosoda W; Yatabe Y; Niwa Y; Yoshimura K; Bhatia V; Fujita J; Yamao K
J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):757-65. PubMed ID: 26148131
[TBL] [Abstract][Full Text] [Related]
17. Invasive carcinoma derived from intraductal papillary mucinous carcinoma of the pancreas.
Nakagohri T; Konishi M; Inoue K; Tanizawa Y; Kinoshita T
Hepatogastroenterology; 2004; 51(59):1480-3. PubMed ID: 15362782
[TBL] [Abstract][Full Text] [Related]
18. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
19. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.
Chari ST; Yadav D; Smyrk TC; DiMagno EP; Miller LJ; Raimondo M; Clain JE; Norton IA; Pearson RK; Petersen BT; Wiersema MJ; Farnell MB; Sarr MG
Gastroenterology; 2002 Nov; 123(5):1500-7. PubMed ID: 12404225
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.
Daudé M; Muscari F; Buscail C; Carrère N; Otal P; Selves J; Buscail L; Bournet B
World J Gastroenterol; 2015 Mar; 21(9):2658-67. PubMed ID: 25759534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
